Article

Immunotherapy Implication of Signature-Guided Biomarker Discovery for Trastuzumab-Resistant HER2-Positive Breast Cancer

2020-01-24

Abstract excerpt

Despite the great improvement of patient outcomes by trastuzumab, a monoclonal antibody targeted on HER2-positive breast cancer, approximately 23% of patients with early-stage disease treated with adjuvant trastuzumab either fail to respond or experience recurrence within 10 years, highlighting the importance of identifying which HER2-positive patients would benefit from trastuzumab upfront. Efforts to identify bi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 48dfb2b6-bba7-51e8-b50f-c390a0d6d201
DOI: 10.1101/2020.01.17.20017947

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Immunotherapy Implication of Signature-Guided Biomarker Discovery for Trastuzumab-Resistant HER2-Positive Breast CancerDOI 10.1101/2020.01.17.20017947Read

Identification of markers to predict benefit from trastuzumab treatmentSemantic proximity Read

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast CancerSemantic proximity Read

Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast CancerSemantic proximity Read

Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: New insights into de novo resistance to trastuzumab (Herceptin)Semantic proximity Read

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer PatientsSemantic proximity Read

Basal/HER2 breast carcinomasSemantic proximity Read

Based on whole-exome sequencing to explore the rule of Herceptin and TKI resistance in breast cancer patients.Semantic proximity Read

Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancerSemantic proximity Read

Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin)Semantic proximity Read

The Evolving Landscape of HER2 Targeting in Breast Cancer.Semantic proximity Read

Dissecting the biological heterogeneity of HER2-positive breast cancerSemantic proximity Read

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.Semantic proximity Read